uniQure makes one-shot gene therapies for rare diseases, like HEMGENIX for hemophilia B, aiming to fix the root cause instead of managing symptoms.
Revenue is tiny at USD 0.02B annually, with gross margins swinging wildly (13.98% to 89.53%) and deep net losses around USD 0.20B—no recurring income, just sporadic licensing and supply deals.
Its gene therapy platform and approved HEMGENIX create real barriers, but competition from Pfizer and Sangamo in similar spaces, plus clinical setbacks, are eroding that edge.
Five-factor rating
Sell (sector percentile 14) — value D, growth C-, profitability F, momentum A, revisions C+. Updated daily, sector-relative, identical for every user.
Most active voices on $QURE
@peter_mantas · Peter Mantas · 73 mentions · 11.0K followers
$QURE — what investors on X are saying · SpikePanel
$QUREuniQure N.V. · Biotechnology · $3.4B
Street Buy · PT $57.5 (+0.2%)
$48.37
-1.1%
Event thread
Key events, in time order
15 items
Earnings
Earnings report
D1 -0.9% · +5d +3.0%
Earnings
uniQure Q2 Loss Wider Than Expected, Stifel Raises PT to $71
Post-Q2, Stifel upgrades/raises PT, focus on AMT-130 regulatory path
D1 +9.3% · +5d +10.4%
›3 waves of this story
2026-07-29 Earnings imminent; focus on near-term milestones over revenue/EPS
2026-07-29 Q2 loss of $1.22/share vs $0.81 expected; revenue misses estimates
2026-07-30 Post-Q2, Stifel upgrades/raises PT, focus on AMT-130 regulatory path
13 earlier events›
Analyst
Wolfe Research upgrades to Outperform
D1 +5.3% · +5d +7.5%
产品Bull
AMT-130 Gets FDA Accelerated Approval Path, Q3 Submissions on Track
FDA aligns on potential accelerated approval; US/UK submissions on track for Q3; 4-year data due Sept
D1 +2.3% · +5d -3.2%
›3 waves of this story
2026-07-17 Multiple sources confirm AMT-130 as core, with FDA feedback and Q3 filing shaping regulatory outlook
2026-07-29 Q2 loss of $1.22/share vs consensus $0.81; FDA aligned on accelerated-approval pathway for AMT-130; US/UK submissions on track for Q3 2026
2026-07-29 FDA aligns on potential accelerated approval; US/UK submissions on track for Q3; 4-year data due Sept
Earnings
Earnings report
D1 +9.3% · +5d +10.4%
8-K filing
8-K: Item 2.02, Item 9.01
D1 +9.3% · +5d +10.4%
产品Bull
uniQure Focuses on AMT-130, Targeting Q3 2026 Filing
Multiple reports confirm AMT-130 as core focus; FDA feedback and Q3 filing plan shape regulatory outlook
D1 +2.3% · +5d -3.2%
RegulationBull
Mizuho raises uniQure PT to $68 on FDA meeting, boosted AMT-260 approval conviction
Mizuho ups PT to $68 from $35, keeps Outperform, citing recent FDA Type B meeting and increased conviction in AMT-260 accelerated approval
D1 +78.4% · +5d +2.0%
›4 waves of this story
2026-06-17 uniQure to file BLA in Q3 2026 for Huntington's gene therapy
2026-06-18 FDA rescinds previous demand for more data; UniQure seeks accelerated approval; stock surges 78%
2026-06-20 AMT-260 shows preliminary efficacy in refractory epilepsy with no treatment-related serious adverse events, adding new evidence to gene therapy pipeline
2026-06-25 Mizuho ups PT to $68 from $35, keeps Outperform, citing recent FDA Type B meeting and increased conviction in AMT-260 accelerated approval
8-K filing
8-K: Item 1.01, Item 8.01, Item 9.01
D1 -0.4% · +5d -7.5%
8-K filing
8-K: Item 7.01, Item 8.01, Item 9.01
D1 -4.1% · +5d +6.8%
Analyst
Barclays upgrades to Overweight
D1 -3.9% · +5d +2.6%
8-K filing
8-K: Item 8.01, Item 9.01
D1 +78.4% · +5d +2.0%
8-K filing
8-K: Item 5.02, Item 5.03, Item 5.07, Item 9.01
D1 +1.1% · +5d +76.0%
8-K filing
8-K: Item 2.02, Item 9.01
D1 +2.3% · +5d +37.5%
Earnings
Earnings report
D1 +2.3% · +5d +37.5%
①
Bull vs bear
by direction · sourced
Bull0
None yet
Bear0
None yet
⑩
Discussion
be the first
Be civil · your views are your own
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Event thread
Key events, in time order
15 items
Earnings
Earnings report
D1 -0.9% · +5d +3.0%
Earnings
uniQure Q2 Loss Wider Than Expected, Stifel Raises PT to $71
Post-Q2, Stifel upgrades/raises PT, focus on AMT-130 regulatory path
D1 +9.3% · +5d +10.4%
›3 waves of this story
2026-07-29 Earnings imminent; focus on near-term milestones over revenue/EPS
2026-07-29 Q2 loss of $1.22/share vs $0.81 expected; revenue misses estimates
2026-07-30 Post-Q2, Stifel upgrades/raises PT, focus on AMT-130 regulatory path
Analyst
Wolfe Research upgrades to Outperform
D1 +5.3% · +5d +7.5%
产品Bull
AMT-130 Gets FDA Accelerated Approval Path, Q3 Submissions on Track
FDA aligns on potential accelerated approval; US/UK submissions on track for Q3; 4-year data due Sept
D1 +2.3% · +5d -3.2%
›3 waves of this story
2026-07-17 Multiple sources confirm AMT-130 as core, with FDA feedback and Q3 filing shaping regulatory outlook
2026-07-29 Q2 loss of $1.22/share vs consensus $0.81; FDA aligned on accelerated-approval pathway for AMT-130; US/UK submissions on track for Q3 2026
2026-07-29 FDA aligns on potential accelerated approval; US/UK submissions on track for Q3; 4-year data due Sept
Earnings
Earnings report
D1 +9.3% · +5d +10.4%
10 earlier events›
8-K filing
8-K: Item 2.02, Item 9.01
D1 +9.3% · +5d +10.4%
产品Bull
uniQure Focuses on AMT-130, Targeting Q3 2026 Filing
Multiple reports confirm AMT-130 as core focus; FDA feedback and Q3 filing plan shape regulatory outlook
D1 +2.3% · +5d -3.2%
RegulationBull
Mizuho raises uniQure PT to $68 on FDA meeting, boosted AMT-260 approval conviction
Mizuho ups PT to $68 from $35, keeps Outperform, citing recent FDA Type B meeting and increased conviction in AMT-260 accelerated approval
D1 +78.4% · +5d +2.0%
›4 waves of this story
2026-06-17 uniQure to file BLA in Q3 2026 for Huntington's gene therapy
2026-06-18 FDA rescinds previous demand for more data; UniQure seeks accelerated approval; stock surges 78%
2026-06-20 AMT-260 shows preliminary efficacy in refractory epilepsy with no treatment-related serious adverse events, adding new evidence to gene therapy pipeline
2026-06-25 Mizuho ups PT to $68 from $35, keeps Outperform, citing recent FDA Type B meeting and increased conviction in AMT-260 accelerated approval
